The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results.
Matthew Alexander Lunning
Consultant or Advisory Role - Onyx
Jia Ruan
Consultant or Advisory Role - Celgene
Sumithra Nair
No relevant relationships to disclose
Adam M. Boruchov
No relevant relationships to disclose
Regina Byrne
No relevant relationships to disclose
John F. Gerecitano
No relevant relationships to disclose
Paul A. Hamlin
No relevant relationships to disclose
Beth Inserra
No relevant relationships to disclose
John Leonard
No relevant relationships to disclose
Peggy Lynch
No relevant relationships to disclose
Matthew J. Matasar
No relevant relationships to disclose
Alison J. Moskowitz
No relevant relationships to disclose
Craig Moskowitz
No relevant relationships to disclose
Patricia L. Myskowski
No relevant relationships to disclose
Patrick Nolan
No relevant relationships to disclose
Maria Lia Palomba
No relevant relationships to disclose
Christiane Quefeld
No relevant relationships to disclose
David J. Straus
No relevant relationships to disclose
Andrew David Zelenetz
No relevant relationships to disclose
Steven M. Horwitz
Consultant or Advisory Role - Celgene; Millennium; Seattle Genetics; Spectrum Pharmaceuticals